| 28 0.02 (0.07%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.73 | 1-year : | 38.23 |
| Resists | First : | 28.03 | Second : | 32.73 |
| Pivot price | 27.88  |
|||
| Supports | First : | 27.7 | Second : | 27.51 |
| MAs | MA(5) : | 27.97 |
MA(20) : | 27.85 |
| MA(100) : | 18.2 |
MA(250) : | 14.84 |
|
| MACD | MACD : | 0.6  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 91 |
D(3) : | 89.3 |
| RSI | RSI(14): 82.2 |
|||
| 52-week | High : | 28.14 | Low : | 6.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMAM ] has closed below upper band by 21.3%. Bollinger Bands are 92.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.04 - 28.15 | 28.15 - 28.26 |
| Low: | 27.69 - 27.82 | 27.82 - 27.94 |
| Close: | 27.8 - 28 | 28 - 28.18 |
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Wed, 06 Mar 2024
Ambrx Shareholders Approve Acquisition by Johnson & Johnson - GlobeNewswire
Tue, 20 Feb 2024
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Fri, 26 Jan 2024
AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC ... - PR Newswire
Mon, 15 Jan 2024
J&J Buys Up Ambrx for $2B - San Diego Business Journal
Thu, 11 Jan 2024
Ambrx Biopharma Inc - ADR Shares Close the Week 110.3% Higher - Weekly Wrap - Nasdaq
Tue, 09 Jan 2024
Ambrx Holders Who Bought for Pennies See 6700% Gain on J&J Bid - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 2.192e+007 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 1,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.175e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -48 % |
| Return on Assets (ttm) | 350.9 % |
| Return on Equity (ttm) | -18.7 % |
| Qtrly Rev. Growth | 4.09e+006 % |
| Gross Profit (p.s.) | 0.11 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -1 |
| Price to Book value | 0 |
| Price to Sales | 307.85 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.16e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|